Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C.

Gut - 1 Jun 2015

Aghemo Alessio, De Francesco Raffaele

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzazepines
Share to Carbamates
Share to Heterocyclic Compounds, 3-Ring
Share to Protease Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pyrrolidines

Share to Simeprevir

Share to Sofosbuvir

Share to Uridine Monophosphate

Source

Identifiers

PMID: 25193803
DOI: 10.1136/gutjnl-2014-307958

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C.PMID 25193803Read ↗

Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C.Semantic proximity Read ↗

Sofosbuvir/velpatasvir (Epclusa) for hepatitis C.Semantic proximity Read ↗

Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use programSemantic proximity Read ↗

Drugs for hepatitis C: unlocking a new mechanism of action.Semantic proximity Read ↗

Daclatasvir plus sofosbuvir regimen sheds promising light on future hepatitis C virus genotype 3 therapies.Semantic proximity Read ↗

Hepatitis B therapy: the plot thickens.Semantic proximity Read ↗

No compelling reason to adopt new antivirals whenever it is reasonable to wait.Semantic proximity Read ↗

Focus on hepatitis. Final APRICOT, ACTG A5071 results.Semantic proximity Read ↗

LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather*Semantic proximity Read ↗

IDSA update from the city of brotherly love.Semantic proximity Read ↗

A tale of two drugs: Molnupiravir and PaxlovidSemantic proximity Read ↗

Management of direct-acting antiviral agent failuresSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.